Enhancing Therapeutic Efficacy of Donepezil by Combined Therapy: A Comprehensive Review

Author(s): Xi Rong, Liwei Jiang*, Meijie Qu, Syed Shams ul Hassan, Zongchao Liu

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 3 , 2021

Become EABM
Become Reviewer
Call for Editor


Combination therapy involving different therapeutic strategies mostly provides more rapid and effective results as compared to monotherapy in diverse areas of clinical practice. The most worldwide famous acetylcholinesterase inhibitor (AChEIs) donepezil for its dominant role in Alzheimer’s disease (AD) has also attracted the attention of many pharmaceuticals due to its promising pharmacological potencies such as neuroprotective, muscle relaxant, and sleep inducer. Recently, a combination of donepezil with other agents has displayed better desirable results in managing several disorders, including the most common Alzheimer’s disease (AD). This study involves all the data regarding the therapeutic effect of donepezil in its combination with other agents and explains its therapeutic targets and mode of action. Furthermore, this review also puts light on the current status of donepezil with other agents in clinical trials. The combination therapy of donepezil with symptomatic relief drugs and disease-modifying agents opens a new road for treating multiple pathological disorders. To the best of our knowledge, this is the first report encircling all the pharmacologic effects of donepezil in its combination therapy with other agents and their current status in clinical trials.

Keywords: Donepezil, acetylcholinesterase inhibitor, combination therapy, Alzheimer's disease, mode of action, clinical trials, pharmaceuticals.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 12 February, 2021
Page: [332 - 344]
Pages: 13
DOI: 10.2174/1381612826666201023144836
Price: $65

Article Metrics

PDF: 70